NOVOTECH HEALTH HOLDINGS PTE LTD


Associated tags: Drug development, Fine chemical

Locations: SOUTH CAROLINA, APAC, AUSTRALIA, INDIA, SOUTH AFRICA, PA, TOKYO, WASHINGTON, SINGAPORE, JAPAN, AFRICA, SWITZERLAND, BEIJING, MIDDLE EAST, AMERICAS, IL, SEOUL, NEW ZEALAND, TAIWAN, KOREA, ASIA, US, CHINA

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
Wednesday, February 15, 2023

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific

Retrieved on: 
Friday, February 10, 2023

SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas.

Key Points: 
  • SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas.
  • According to the report, titled "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", in 2022 Asia Pacific accounted for a 58% share of the approximately 3,600 Phase I trials initiated globally in 2022.
  • The report found that Asia Pacific also leads phase I trials across the top therapeutic areas.
  • View "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", the new report, on this link: https://tinyurl.com/novotech-global-report
    See the report for Phase 1 location and therapeutic area analysis including:

Asia Pacific Cell & Gene Research Growing 50% Faster than ROW

Retrieved on: 
Friday, February 3, 2023

SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.

Key Points: 
  • SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.
  • Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).
  • The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.
  • The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021.

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

Retrieved on: 
Thursday, January 12, 2023

CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.

Key Points: 
  • CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.
  • Novotech CEO Dr. John Moller said: "CBR will provide decades of FDA regulatory experience for our biotech clients.
  • Navigating novel product development and achieving multiple approvals has built our expertise to support the complex development needs of clients worldwide which will now support Novotech clients.
  • We look forward to working with Novotech clients to support their drug development programs in the US and globally.

Novotech is Gold Sponsor at Biotech Showcase 2023

Retrieved on: 
Tuesday, December 20, 2022

SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.

Key Points: 
  • SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.
  • Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.
  • Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.
  • The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific.

Data Shows 50% of New Trials Have Sites in Asia Pacific

Retrieved on: 
Sunday, December 18, 2022

SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.

Key Points: 
  • SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.
  • According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.
  • The data shows almost 12,900 of the new trials had sites in Asia Pacific.
  • - Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

Retrieved on: 
Tuesday, December 6, 2022

SYDNEY, AU, Dec 6, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.

Key Points: 
  • SYDNEY, AU, Dec 6, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.
  • Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
  • Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain.
  • Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US.